The Zacks Analyst Blog Highlights: Walgreens, Express Scripts Holding, Haemonetics, ResMed and Eli Lilly

    The Zacks Analyst Blog Highlights: Walgreens, Express Scripts Holding,
                      Haemonetics, ResMed and Eli Lilly

PR Newswire

CHICAGO, June 24, 2013

CHICAGO, June 24, 2013 /PRNewswire/ --Zacks.com announces the list of stocks
featured in the Analyst Blog. Every day the Zacks Equity Research analysts
discuss the latest news and events impacting stocks and the financial markets.
Stocks recently featured in the blog include Walgreens (NYSE:WAG-Free Report),
Express Scripts Holding Company (Nasdaq:ESRX-Free Report), Haemonetics
Corporation (NYSE:HAE-Free Report), ResMed Inc. (NYSE:RMD-Free Report) and Eli
Lilly and Company (NYSE:LLY-Free Report).

(Logo: http://photos.prnewswire.com/prnh/20101027/ZIRLOGO) 

Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of
the Day pick for free.

Here are highlights from Friday's Analyst Blog:

Will Walgreens Miss 3Q Earnings?



Walgreens (NYSE:WAG-Free Report) is set to report third-quarter fiscal 2013
results before the opening bell on Tuesday, Jun 25. In the second quarter,
this drug retail giant posted a 1.05% positive earnings surprise after two
consecutive misses. Let's see how things are shaping up prior to the
announcement.

Factors to Consider this Quarter

As reported earlier, Walgreens' total sales came in at $18.34 in the third
quarter of fiscal 2013. Despite sales growth of 3.3% year over year, the
quarterly sales trailed the Zacks Consensus Estimate for the fifth time in a
row.

Nonetheless, the company witnessed higher comparable store sales and front-end
comparable store sales. Additionally, comparable pharmacy sales improved in
the third quarter.

As it crossed the halfway mark of fiscal 2013, things started looking up for
Walgreens. Following the reconciliation withExpress Scripts Holding Company
(Nasdaq:ESRX-Free Report), Walgreens is sanguine about increasing returns of
customers. This is reflected in the higher number of prescriptions filled at
the company's comparable stores in the third quarter.

Walgreens' timely progress to deliver first-year synergy targets following its
Alliance Boots deal in encouraging. Notably, the company's third-quarter
numbers will reflect whether its deal-making spree is paying off.

However, the generic wave in the pharmaceutical industry continues to hurt
revenues. The company also faces tough industry conditions and competitive
headwinds.

Earnings Whispers?

Our proven model does not conclusively show that Walgreens will likely beat
earnings estimates this quarter. That is because a stock needs to have both a
positive Earnings ESP (Read: Zacks Earnings ESP: A Better Method) as well as a
Zacks Rank of #1, 2 or 3 for this to happen. This is not the case here as you
will see below.

Zacks Earnings ESP: The Most Accurate Estimate stands at $0.90 while the Zacks
Consensus Estimate is also at $0.90. This comes to a difference of 0.00%.

Zacks Rank #3 (Hold): Walgreens carries a Zacks Rank #3 (Hold), which
increases the predictive power of ESP. However, the Zacks Rank #3 when
combined with a 0.00% ESP makes surprise prediction difficult.

Other Stocks to Consider

Here are some other companies you may want to consider as our model shows that
these have the right combination of ingredients to post an earnings beat this
quarter: 

Haemonetics Corporation (NYSE:HAE-Free Report), Earnings ESP of +2.13% and a
Zacks Rank #1 (Strong Buy)

ResMed Inc. (NYSE:RMD-Free Report), Earnings ESP of +4.84% and a Zacks Rank #3
(Hold)



Label Updates for Lilly Drugs

Eli Lilly and Company (NYSE:LLY-Free Report) and Boehringer Ingelheim
Pharmaceuticals, Inc. recently announced that the labels for their diabetes
drugs, Tradjenta (linagliptin) and Jentadueto (linagliptin plus metformin)
will be updated in the US. Eli Lilly and Boehringer Ingelheim said that the
label updates had been approved by the US Food and Drug Administration (FDA).

The label updates will provide information needed to ensure the proper use of
these medicines by physicians, pharmacists and patients.

Eli Lilly and Boehringer Ingelheim said that the Prescribing Information (PI)
section of the labels for Tradjenta and Jentadueto will carry additional
information regarding the risk of pancreatitis. The Important Limitations of
Use sections within the Indications and Usage sections will be updated with
the information that both drugs have not been studied in patients with a
history of pancreatitis.

Moreover, this section will state that it is not known whether patients with a
history of pancreatitis will be at a higher risk for the development of
pancreatitis while using Tradjenta or Jentadueto.

Meanwhile, the Warnings and Precautions section will include information
regarding post marketing reports of acute pancreatitis, including fatal
pancreatitis, in patients taking linagliptin.

The Patient Counseling Information section will also include information about
the potential risk and symptoms of pancreatitis. This section of the label
carries instructions asking healthcare providers to inform their patients
about the potential risks and benefits associated with the use of Tradjenta or
Jentadueto.

Eli Lilly and Boehringer Ingelheim also said that they will inform physicians
prescribing dipeptidyl peptidase 4 (DPP-4) inhibitors and pharmacists about
the label update.

Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of
the Day pick for free.



About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative
analysis to help investors know what stocks to buy and which to sell for the
long-term.

Continuous coverage is provided for a universe of 1,150 publicly traded
stocks. Our analysts are organized by industry which gives them keen insights
to developments that affect company profits and stock performance.
Recommendations and target prices are six-month time horizons.

Zacks "Profit from the Pros" e-mail newsletter provides highlights of the
latest analysis from Zacks Equity Research. Subscribe to this free newsletter
today.

About Zacks

Zacks.com is a property of Zacks Investment Research, Inc., which was formed
in 1978. The later formation of the Zacks Rank, a proprietary stock picking
system; continues to outperform the market by nearly a 3 to 1 margin. The best
way to unlock the profitable stock recommendations and market insights of
Zacks Investment Research is through our free daily email newsletter; Profit
from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED
to be worth your time! Register for your free subscription to Profit from the
Pros.



Get the full Report on WAG - FREE

Get the full Report on ESRX - FREE

Get the full Report on HAE - FREE

Get the full Report on RMD - FREE

Get the full Report on LLY - FREE



Follow us on Twitter: http://twitter.com/zacksresearch

Join us on Facebook:
http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts

Zacks Investment Research is under common control with affiliated entities
(including a broker-dealer and an investment adviser), which may engage in
transactions involving the foregoing securities for the clients of such
affiliates.



Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
http://www.zacks.com



Past performance is no guarantee of future results. Inherent in any investment
is the potential for loss. This material is being provided for informational
purposes only and nothing herein constitutes investment, legal, accounting or
tax advice, or a recommendation to buy, sell or hold a security. No
recommendation or advice is being given as to whether any investment is
suitable for a particular investor. It should not be assumedthat any
investments in securities, companies, sectors or markets identified and
described were or will be profitable. All information is current as of the
date of herein andis subject to change without notice. Any views or opinions
expressed may not reflect those of the firm as a whole. Zacks Investment
Research does not engage in investment banking, market making or asset
management activities of any securities. These returns are from hypothetical
portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced
monthly with zero transaction costs. These are not the returns of actual
portfolios of stocks. The S&P 500 is an unmanaged index. Visit
http://www.zacks.com/performance for information about the performance numbers
displayed in this press release.



SOURCE Zacks Investment Research, Inc.

Website: http://www.zacks.com